July 2016

An increasing number of investigators are focused on developing therapies specifically for cholangiocarcinoma as rates for the disease are rising. 

In 2012, the Society for Immunotherapy of Cancer convened a worldwide consortium to validate the Immunoscore as a standardized assay for use in routine clinical settings.

Liver metastases have long led to a poor diagnosis for patients with metastatic colorectal cancer (mCRC), especially when the metastases are unresectable. However, an increasing number of adjunct techniques can treat the liver until surgery becomes possible, and there are also alternatives to surgery for nonresectable patients.

Deciding the sequencing order of therapies for patients with ALK-positive non–small cell lung cancer (NSCLC) is a challenge, as new information on next-generation tyrosine kinase inhibitors (TKIs) comes to light, says Robert Doebele, MD, PhD. Testing for ALK translocations can help to determine which therapies NSCLC patients should be receiving, but questions regarding the sequencing of ALK inhibitors still remain.

Research is making only modest progress in the discovery of receptor tyrosine kinase inhibitors that show benefit in the treatment of sarcomas, Gary K. Schwartz, MD, argued during a presentation at the 2016 ASCO Annual Meeting.

Among immunotherapies PD-1 inhibitors are gaining the most attention for<br /> the treatment of patients with sarcomas.